We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-8.51%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$995M
AUM Growth
-$504M
(-34%)
Cap. Flow
-$395M
Cap. Flow
% of AUM
-39.65%
Top 10 Holdings %
Top 10 Hldgs %
49.03%
Holding
79
New
15
Increased
11
Reduced
25
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$29.9M |
| 2 |
Cigna
CI
|
+$24.9M |
| 3 |
Eli Lilly
LLY
|
+$21.2M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$18.3M |
| 5 |
Intuitive Surgical
ISRG
|
+$17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Envista
NVST
|
+$44.5M |
| 2 |
AbbVie
ABBV
|
+$41.2M |
| 3 |
Teleflex
TFX
|
+$35.2M |
| 4 |
Abbott
ABT
|
+$32.4M |
| 5 |
CVS Health
CVS
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.68% |
| 2 | Financials | 0.12% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Syndax Pharmaceuticals
SNDX
$1.75B
| $17.8M | 1.79% |
923,400
-257,100
| -22% | -$4.28M |
|
27
Agilent Technologies
A
$39.7B
| $16.4M | 1.65% |
+138,280
| New | +$17M |
|
|
28
Intuitive Surgical
ISRG
$132B
| $14.5M | 1.46% |
+72,490
| New | +$17M |
|
29
Becton Dickinson
BDX
$46.8B
| $13.7M | 1.38% |
55,710
-89,287
| -62% | -$22.7M |
|
30
Universal Health Services
UHS
$10.3B
| $13.5M | 1.36% |
134,040
-94,370
| -41% | -$11.8M |
|
31
McKesson
MCK
$99.5B
| $11.4M | 1.15% |
35,040
-60,760
| -63% | -$19.4M |
|
|
KZR
32
DELISTED
Kezar Life Sciences
KZR
| $10M | 1.01% |
+120,988
| New | +$10.7M |
|
33
Cooper Companies
COO
$14.6B
| $9.63M | 0.97% |
123,080
-311,280
| -72% | -$27.5M |
|
34
Zimmer Biomet
ZBH
$19.2B
| $7.57M | 0.76% |
+72,020
| New | +$8.54M |
|
35
iShares Biotechnology ETF
IBB
$9.54B
| $6.34M | 0.64% |
53,940
+25,720
| +91% | +$3.05M |
|
36
Hyperfine
HYPR
$97.3M
| $6.13M | 0.62% |
2,749,400
+999,400
| +57% | +$2.94M |
|
37
DexCom
DXCM
$31.7B
| $5.57M | 0.56% |
+74,780
| New | +$6.82M |
|
|
AFMD
38
DELISTED
Affimed
AFMD
| $4.77M | 0.48% |
172,193
| – | – |
|
39
State Street Health Care Select Sector SPDR ETF
XLV
$42.3B
| $4.44M | 0.45% |
+34,610
| New | +$4.54M |
|
|
RAPT
40
DELISTED
RAPT Therapeutics
RAPT
| $3.96M | 0.4% |
27,146
-5,873
| -18% | -$783K |
|
41
Teva Pharmaceuticals
TEVA
$40.6B
| $3.76M | 0.38% |
+499,640
| New | +$4.35M |
|
42
Quanterix
QTRX
$177M
| $3.26M | 0.33% |
201,560
-44,980
| -18% | -$925K |
|
|
LKFT
43
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
| $3.08M | 0.31% |
55,280
+31,540
| +133% | +$1.87M |
|
|
MRUS
44
DELISTED
Merus
MRUS
| $2.7M | 0.27% |
119,200
+7,440
| +7% | +$155K |
|
45
BioCryst Pharmaceuticals
BCRX
$2.34B
| $2.54M | 0.25% |
239,820
+11,370
| +5% | +$117K |
|
|
CCXI
46
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.48M | 0.25% |
+100,000
| New | +$2.2M |
|
47
CALL
Align Technology
ALGN
$12.5B
| $2.37M | 0.24% |
+10,000
| New | +$3.07M |
|
|
IMGN
48
DELISTED
Immunogen Inc
IMGN
| $2.25M | 0.23% |
500,000
-810,340
| -62% | -$3.52M |
|
49
Insulet
PODD
$9.43B
| $1.56M | 0.16% |
+7,150
| New | +$1.63M |
|
50
Geron
GERN
$1.02B
| $1.55M | 0.16% |
1,000,000
+100,000
| +11% | +$141K |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2022 Portfolio in Review
As of Q2 2022, HealthCor Management held 79 positions worth $995M, down 34% from $1.5B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
HealthCor Management withdrew a net $395M in Q2 2022, closing 21 positions and reducing 25 holdings. Its most notable exit was Envista, an estimated $44.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, HealthCor Management opened a new position in Hologic worth $27.9M.
- HealthCor Management's largest Q2 2022 buy was Hologic: 402,110 shares worth $27.9M.
- HealthCor Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $18.3M increase.
- HealthCor Management's biggest Q2 2022 reduction was Abbott, cutting an estimated $32.4M.
- HealthCor Management fully exited Envista in Q2 2022, selling an estimated $44.5M.
- HealthCor Management's ten largest holdings make up 49% of its $995M portfolio in Q2 2022.
- HealthCor Management opened 15 new positions and closed 21 in Q2 2022.
- HealthCor Management's portfolio value fell 34% quarter-over-quarter to $995M.
Based on HealthCor Management's 13F filing for Q2 2022, filed 15 Aug 2022.